XSHE
002566
Market cap347mUSD
Oct 09, Last price
7.08CNY
1D
0.71%
1Q
15.88%
Jan 2017
-44.69%
IPO
-46.08%
Name
Jilin Jian Yisheng Pharmaceutical Co Ltd
Chart & performance
P/E
80.80
P/S
3.66
EPS
0.09
Div yield, %
1.42%
Shrs. gr., 5y
0.01%
Rev. gr., 5y
-6.12%
Revenues
640m
-4.23%
Net income
29m
-44.32%
CFO
99m
+67.51%
Dividend
May 29, 20260.08 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Jilin Jian Yisheng Pharmaceutical Co., Ltd. is an enterprise based in Ji'an, China, established in 1997. The company specializes in the production and distribution of a diverse array of goods across the Chinese market. Its offerings include various pharmaceutical products, traditional Chinese herbal medicines, cosmetic items, and food products. Within its medical and health divisions, the firm provides goods in formats such as capsules, injections, tablets, and granules, with a particular emphasis on specialized medicinal products derived from Ginseng, as well as a selection of bee-related products.
Key people
Xin Zhang
Vice Chairman of the Board · since 2022
Xiaomin Xue
General Manager · since 2022
Jiantao Bi
Chief Financial Officer, Deputy General Manager, Director · since 2022
Tiejun Li
Deputy General Manager, Secretary of the Board · since 2021
Wei Meng
Chief Marketing Officer, Deputy General Manager
Jianjun Qu
Director
Xiaole Tong
Director
Yisheng Zhang
Chairman of the Board · since 2000
Ming Li
Independent Director
Chaoyang Liu
Independent Director · since 2025
Independent Director · since 2025
Shan Xu
Independent Director
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||